Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 19/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.56 |
| ▸ | HTR3A | P46098 | 2/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3815871 | 1.00 | HRH3 (0.57) | HRH3KCNH2CYP3A4PDE4BHTR3A | |
| SCHEMBL3822481 | 1.00 | HRH3 (0.57) | HRH3KCNH2CYP3A4PDE4BHTR3A | |
| SCHEMBL1776915 | 0.84 | HRH3 (0.61) | HRH3KCNH2CYP3A4PDE4B | |
| SCHEMBL1777481 | 0.84 | HRH3 (0.60) | HRH3KCNH2CYP3A4PDE4B | |
| SCHEMBL1778073 | 0.83 | HRH3 (0.59) | HRH3KCNH2CYP3A4PDE4B | |
| SCHEMBL13437928 | 0.82 | HRH3 (0.62) | HRH3KCNH2HTR3ACHRM2SLC6A2 | |
| SCHEMBL1777134 | 0.81 | HRH3 (0.57) | HRH3KCNH2CYP3A4PDE4B | |
| SCHEMBL13725587 | 0.81 | HRH3 (0.56) | HRH3KCNH2CYP3A4 | |
| SCHEMBL27738571 | 0.81 | HRH3 (0.59) | HRH3KCNH2CYP3A4PDE4BHTR3A | |
| SCHEMBL4921549 | 0.80 | HRH3 (0.58) | HRH3KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904484-B1 | COMPOUNDS | GLAXO GROUP LTD (GB) | 2009-08-26 | — | — | EP | disclosed |
| EP-1904484-B1 | COMPOUNDS | GLAXO GROUP LTD (GB) | 2009-08-26 | — | — | EP | disclosed |
| US-20080275027-A1 | Piperazinone Derivatives Useful as Histamine H3 Receptor Antagonists and/or Inverse Agonists | GLAXO GROUP LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080275027-A1 | Piperazinone Derivatives Useful as Histamine H3 Receptor Antagonists and/or Inverse Agonists | GLAXO GROUP LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080275027-A1 | Piperazinone Derivatives Useful as Histamine H3 Receptor Antagonists and/or Inverse Agonists | GLAXO GROUP LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080207638-A1 | Compounds | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O (GB) | 2008-08-28 | — | — | US | disclosed |
| US-20080207638-A1 | Compounds | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O (GB) | 2008-08-28 | — | — | US | disclosed |
| US-20080207638-A1 | Compounds | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O (GB) | 2008-08-28 | — | — | US | disclosed |
| EP-1906964-A1 | PIPERAZINONE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR ANTAGONISTS AND/OR INVERSE AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-04-09 | — | — | EP | disclosed |
| EP-1904484-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007009739-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009739-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009741-A1 | PIPERAZINONE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR ANTAGONISTS AND/OR INVERSE AGONISTS | GLAXO GROUP LIMITED (GB) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009741-A1 | PIPERAZINONE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR ANTAGONISTS AND/OR INVERSE AGONISTS | GLAXO GROUP LIMITED (GB) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207638-A1 | Compounds | CMA1, MRGPRX2, HRH2 | HRH3 16/4885KCNH2 1588/4885CYP3A4 185/4885 |
| US-20080275027-A1 | Piperazinone Derivatives Useful as Histamine H3 Receptor Antagonists and/or Inverse Agonists | HRH3, HRH1, HRH4 | HRH3 1/4885KCNH2 497/4885CYP3A4 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.